$APYX
Apyx Medical Corp

2020 Q2 Form 10-Q Financial Statement

#000071913520000057 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q2
Revenue $4.296M $4.997M $6.649M
YoY Change -35.39% -11.23% 80.14%
Cost Of Revenue $2.202M $2.013M $1.975M
YoY Change 11.49% -2.57% 71.14%
Gross Profit $2.094M $2.984M $4.674M
YoY Change -55.2% -16.25% 84.23%
Gross Profit Margin 48.74% 59.72% 70.3%
Selling, General & Admin $2.189M $3.796M $3.037M
YoY Change -27.92% 28.37% 37.23%
% of Gross Profit 104.54% 127.21% 64.98%
Research & Development $975.0K $980.0K $888.0K
YoY Change 9.8% 34.25% 16.38%
% of Gross Profit 46.56% 32.84% 19.0%
Depreciation & Amortization $230.0K $214.0K $130.0K
YoY Change 76.92% 10.31% -24.42%
% of Gross Profit 10.98% 7.17% 2.78%
Operating Expenses $8.261M $10.48M $9.096M
YoY Change -9.18% 12.73% 66.29%
Operating Profit -$6.167M -$7.492M -$4.422M
YoY Change 39.46% 30.75% 50.77%
Interest Expense $8.000K $6.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$15.00K $636.0K $203.0K
YoY Change -107.39% 396.88% 2437.5%
Pretax Income -$6.182M -$6.856M -$4.219M
YoY Change 46.53% 22.38% 44.24%
Income Tax -$1.492M -$4.905M $76.00K
% Of Pretax Income
Net Earnings -$4.690M -$1.951M -$4.338M
YoY Change 8.11% -58.32% 47.65%
Net Earnings / Revenue -109.17% -39.04% -65.24%
Basic Earnings Per Share -$0.14 -$0.13
Diluted Earnings Per Share -$0.14 -$57.05K -$0.13
COMMON SHARES
Basic Shares Outstanding 34.19M shares 34.17M shares 34.04M shares
Diluted Shares Outstanding 34.19M shares

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.20M $51.40M $67.40M
YoY Change -31.45% -29.88% 753.16%
Cash & Equivalents $46.16M $51.38M $67.36M
Short-Term Investments $0.00
Other Short-Term Assets $4.000M $4.400M $2.000M
YoY Change 100.0% 214.29% 53.85%
Inventory $5.257M $5.872M $6.392M
Prepaid Expenses
Receivables $6.306M $6.122M $5.292M
Other Receivables $1.671M $1.302M $0.00
Total Short-Term Assets $69.84M $74.17M $81.96M
YoY Change -14.78% -13.07% 268.71%
LONG-TERM ASSETS
Property, Plant & Equipment $6.440M $6.543M $6.300M
YoY Change 2.22% 8.78% -0.22%
Goodwill $185.0K
YoY Change 0.0%
Intangibles $185.0K
YoY Change -87.75%
Long-Term Investments
YoY Change
Other Assets $560.0K $482.0K $445.0K
YoY Change 25.84% 38.9% 564.18%
Total Long-Term Assets $7.986M $7.946M $6.926M
YoY Change 15.3% 21.5% -17.8%
TOTAL ASSETS
Total Short-Term Assets $69.84M $74.17M $81.96M
Total Long-Term Assets $7.986M $7.946M $6.926M
Total Assets $77.83M $82.12M $88.88M
YoY Change -12.44% -10.6% 189.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.206M $2.535M $1.641M
YoY Change 34.43% 68.55% -40.22%
Accrued Expenses $6.911M $7.586M $5.848M
YoY Change 18.18% 8.23% 141.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $400.0K $400.0K
YoY Change
Total Short-Term Liabilities $9.635M $10.60M $7.897M
YoY Change 22.01% 23.04% 26.62%
LONG-TERM LIABILITIES
Long-Term Debt $400.0K $400.0K $100.0K
YoY Change 300.0% 300.0% -95.72%
Other Long-Term Liabilities $765.0K $520.0K $300.0K
YoY Change 155.0% 168.04%
Total Long-Term Liabilities $765.0K $520.0K $400.0K
YoY Change 91.25% 168.04% -82.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.635M $10.60M $7.897M
Total Long-Term Liabilities $765.0K $520.0K $400.0K
Total Liabilities $10.99M $11.69M $8.304M
YoY Change 32.36% 29.48% -8.55%
SHAREHOLDERS EQUITY
Retained Earnings $7.876M $12.57M $24.32M
YoY Change -67.62% -56.09% -181.88%
Common Stock $34.00K $34.00K $34.00K
YoY Change 0.0% 0.0% 3.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.84M $70.43M $79.44M
YoY Change
Total Liabilities & Shareholders Equity $77.83M $82.12M $88.88M
YoY Change -12.44% -10.6% 189.96%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q2
OPERATING ACTIVITIES
Net Income -$4.690M -$1.951M -$4.338M
YoY Change 8.11% -58.32% 47.65%
Depreciation, Depletion And Amortization $230.0K $214.0K $130.0K
YoY Change 76.92% 10.31% -24.42%
Cash From Operating Activities -$5.020M -$7.407M -$5.590M
YoY Change -10.2% 45.55% 880.7%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K $90.00K -$400.0K
YoY Change -77.5% -23.08% 110.53%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $40.88M
YoY Change -100.0% -100.0%
Cash From Investing Activities -$90.00K -$90.00K $40.48M
YoY Change -100.22% -100.43% -21405.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K $15.00K 50.00K
YoY Change -240.0% -77.61% -183.33%
NET CHANGE
Cash From Operating Activities -5.020M -$7.407M -5.590M
Cash From Investing Activities -90.00K -$90.00K 40.48M
Cash From Financing Activities -70.00K $15.00K 50.00K
Net Change In Cash -5.180M -$7.432M 34.94M
YoY Change -114.83% -146.98% -4360.98%
FREE CASH FLOW
Cash From Operating Activities -$5.020M -$7.407M -$5.590M
Capital Expenditures -$90.00K $90.00K -$400.0K
Free Cash Flow -$4.930M -$7.497M -$5.190M
YoY Change -5.01% 44.01% 1265.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 apyx Provision For Obsolescence Inventory
ProvisionForObsolescenceInventory
392000 USD
CY2020Q2 apyx Provision For Obsolescence Inventory
ProvisionForObsolescenceInventory
685000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
273000 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Central Index Key
EntityCentralIndexKey
0000719135
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4403000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4702000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
760000 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34312257 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34201895 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34169952 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34201895 shares
us-gaap Inventory Write Down
InventoryWriteDown
400000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-12183
dei Entity Registrant Name
EntityRegistrantName
APYX MEDICAL CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2644611
dei Entity Address Address Line1
EntityAddressAddressLine1
5115 Ulmerton Road,
dei Entity Address City Or Town
EntityAddressCityOrTown
Clearwater
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33760
dei City Area Code
CityAreaCode
727
dei Local Phone Number
LocalPhoneNumber
384-2323
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
APYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34216349 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46156000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58812000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6306000 USD
CY2020Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1671000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7987000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1233000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
5257000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5068000 USD
CY2020Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
6443000 USD
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
426000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4008000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84745000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4296000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
295000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3207000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
69841000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
76733000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6440000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6618000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
350000 USD
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
691000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
653000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
560000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
391000 USD
CY2020Q2 us-gaap Assets
Assets
77827000 USD
CY2019Q4 us-gaap Assets
Assets
84745000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2206000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2438000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6911000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9396000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000 USD
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
266000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
229000 USD
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
140000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
140000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9635000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12311000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
177000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
235000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
414000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
421000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
765000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
519000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
10991000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
13486000 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
34000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
34000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58926000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
56708000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
7876000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
14517000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
66836000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
71259000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77827000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6649000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9293000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12278000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2202000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1975000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4215000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4041000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
2094000 USD
CY2020Q2 us-gaap Professional Fees
ProfessionalFees
1658000 USD
CY2019Q2 us-gaap Gross Profit
GrossProfit
4674000 USD
us-gaap Gross Profit
GrossProfit
5078000 USD
us-gaap Gross Profit
GrossProfit
8237000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
975000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
888000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1955000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1618000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.14
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.13
CY2019Q2 us-gaap Professional Fees
ProfessionalFees
1661000 USD
us-gaap Professional Fees
ProfessionalFees
4047000 USD
us-gaap Professional Fees
ProfessionalFees
3779000 USD
CY2020Q2 us-gaap Salaries And Wages
SalariesAndWages
3439000 USD
CY2019Q2 us-gaap Salaries And Wages
SalariesAndWages
3510000 USD
us-gaap Salaries And Wages
SalariesAndWages
6750000 USD
us-gaap Salaries And Wages
SalariesAndWages
6998000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2189000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3037000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5985000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5994000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
8261000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
9096000 USD
us-gaap Operating Expenses
OperatingExpenses
18737000 USD
us-gaap Operating Expenses
OperatingExpenses
18389000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6167000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4422000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13659000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10152000 USD
CY2020Q2 us-gaap Interest Income Operating
InterestIncomeOperating
7000 USD
CY2019Q2 us-gaap Interest Income Operating
InterestIncomeOperating
403000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
223000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
826000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
8000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
14000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-14000 USD
CY2019Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-200000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
412000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-495000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
203000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
621000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
331000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6182000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4219000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13038000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9821000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1492000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6397000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4690000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4295000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6641000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9903000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
70429000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1097000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.19
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.30
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
82831000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
856000 USD
CY2019Q2 apyx Stock Swap To Acquire Options Amount
StockSwapToAcquireOptionsAmount
0 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4295000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
79440000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1097000 USD
CY2020Q2 apyx Stock Swap To Acquire Options Amount
StockSwapToAcquireOptionsAmount
0 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4690000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
66836000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
87177000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2051000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2051000 USD
apyx Stock Swap To Acquire Options Amount
StockSwapToAcquireOptionsAmount
0 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9903000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
79440000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
71259000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2146000 USD
apyx Stock Swap To Acquire Options Amount
StockSwapToAcquireOptionsAmount
0 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6641000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
66836000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6641000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9903000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
439000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
316000 USD
apyx Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
413000 USD
apyx Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
36000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2146000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2051000 USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
164000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
486000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-238000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1195000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1333000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7427000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
879000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
571000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1015000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
218000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2241000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
236000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12433000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10675000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
518000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
18884000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80726000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61324000 USD
apyx Proceeds From Stock Options Exercised And Warrants Exercised
ProceedsFromStockOptionsExercisedAndWarrantsExercised
72000 USD
apyx Proceeds From Stock Options Exercised And Warrants Exercised
ProceedsFromStockOptionsExercisedAndWarrantsExercised
115000 USD
apyx Repaymentof Finance Lease Liabilities
RepaymentofFinanceLeaseLiabilities
120000 USD
apyx Repaymentof Finance Lease Liabilities
RepaymentofFinanceLeaseLiabilities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-48000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
115000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12656000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50764000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58812000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16596000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46156000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67360000 USD
us-gaap Interest Paid Net
InterestPaidNet
8000 USD
us-gaap Interest Paid Net
InterestPaidNet
14000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
54000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
248000 USD
apyx Non Cash Proceeds From Stock Options And Warrants Exercised
NonCashProceedsFromStockOptionsAndWarrantsExercised
49000 USD
apyx Non Cash Proceeds From Stock Options And Warrants Exercised
NonCashProceedsFromStockOptionsAndWarrantsExercised
757000 USD
apyx Lease Adoption
LeaseAdoption
0 USD
apyx Lease Adoption
LeaseAdoption
212000 USD
apyx Capitalization Of Lease Non Cash
CapitalizationOfLeaseNonCash
0 USD
apyx Capitalization Of Lease Non Cash
CapitalizationOfLeaseNonCash
207000 USD
apyx Capitalization Of Lease Execution
CapitalizationOfLeaseExecution
150000 USD
apyx Capitalization Of Lease Execution
CapitalizationOfLeaseExecution
0 USD
apyx Non Cash Transfer Of Other Assets To Fixed Assets
NonCashTransferOfOtherAssetsToFixedAssets
0 USD
apyx Non Cash Transfer Of Other Assets To Fixed Assets
NonCashTransferOfOtherAssetsToFixedAssets
42000 USD
apyx Non Cash Transfers Of Inventory To From Fixed Assets
NonCashTransfersOfInventoryToFromFixedAssets
-34000 USD
apyx Non Cash Transfers Of Inventory To From Fixed Assets
NonCashTransfersOfInventoryToFromFixedAssets
262000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
RECENT ACCOUNTING PRONOUNCEMENTS <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments—Credit Losses (Topic 326).</span><span style="font-family:inherit;font-size:10pt;"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="font-family:inherit;font-size:10pt;">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div>
CY2020Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2441000 USD
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2935000 USD
CY2020Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1504000 USD
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1209000 USD
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1997000 USD
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1316000 USD
CY2020Q2 us-gaap Inventory Gross
InventoryGross
5942000 USD
CY2019Q4 us-gaap Inventory Gross
InventoryGross
5460000 USD
CY2020Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
685000 USD
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
392000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
5257000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5068000 USD
CY2020Q2 us-gaap Inventory Write Down
InventoryWriteDown
400000 USD
CY2020Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
726000 USD
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
694000 USD
CY2020Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 USD
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1306000 USD
CY2020Q2 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
531000 USD
CY2019Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
877000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1043000 USD
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
439000 USD
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
452000 USD
CY2020Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
626000 USD
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1170000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1383000 USD
CY2020Q2 apyx Joint And Several Payroll Liability
JointAndSeveralPayrollLiability
1045000 USD
CY2019Q4 apyx Joint And Several Payroll Liability
JointAndSeveralPayrollLiability
1045000 USD
CY2020Q2 apyx Uncertain Tax Positions Liability
UncertainTaxPositionsLiability
1573000 USD
CY2019Q4 apyx Uncertain Tax Positions Liability
UncertainTaxPositionsLiability
1491000 USD
CY2020Q2 apyx Other Accrued Expenses And Liabilities Current
OtherAccruedExpensesAndLiabilitiesCurrent
928000 USD
CY2019Q4 apyx Other Accrued Expenses And Liabilities Current
OtherAccruedExpensesAndLiabilitiesCurrent
978000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6911000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9396000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4690000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4295000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6641000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9903000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34186000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33384000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34181000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33363000 shares
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.14
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.13
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.19
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.30
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1097000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2146000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
856000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2051000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3966858 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1274900 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.18
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
44381 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
211433 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.51
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4985944 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.46
CY2020Q2 apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
17665 shares
CY2019Q2 apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
17221 shares
apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
22027 shares
apyx Stock Issued During Period Shares Stock Swaps
StockIssuedDuringPeriodSharesStockSwaps
185951 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.659
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
apyx Cares Act Income Tax Expense Benefit Release Of Valuation Allowance Federal Net Operating Loss Carryforwards
CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards
-3700000 USD
CY2020Q2 apyx Cares Act Income Tax Expense Benefit Related To Current Period Net Income Loss Before Income Taxes
CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes
-1500000 USD
apyx Cares Act Income Tax Expense Benefit Related To Current Period Net Income Loss Before Income Taxes
CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes
-1200000 USD
apyx Cares Act Federal Income Tax Payments Available To Offset Current Period Losses
CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses
3200000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1492000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76000 USD
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.241
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.018
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.491
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.008
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1313000 USD
us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1313000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
260000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
43000 USD
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
82000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1573000 USD
CY2020Q2 us-gaap Purchase Obligation
PurchaseObligation
500000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4296000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6167000 USD
CY2020Q2 us-gaap Interest Income Operating
InterestIncomeOperating
7000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
8000 USD
CY2020Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-14000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1492000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6649000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4422000 USD
CY2019Q2 us-gaap Interest Income Operating
InterestIncomeOperating
403000 USD
CY2019Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-200000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9293000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13659000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
223000 USD
us-gaap Interest Expense
InterestExpense
14000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
412000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6397000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12278000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10152000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
826000 USD
apyx Total Revenue Percent
TotalRevenuePercent
0.246
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-495000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82000 USD
CY2020Q2 apyx Total Revenue Percent
TotalRevenuePercent
0.210
CY2019Q2 apyx Total Revenue Percent
TotalRevenuePercent
0.317
apyx Total Revenue Percent
TotalRevenuePercent
0.312
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4296000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6649000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9293000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12278000 USD

Files In Submission

Name View Source Status
0000719135-20-000057-index-headers.html Edgar Link pending
0000719135-20-000057-index.html Edgar Link pending
0000719135-20-000057.txt Edgar Link pending
0000719135-20-000057-xbrl.zip Edgar Link pending
a2020q210-q.htm Edgar Link pending
a2020q210-qexhibit311.htm Edgar Link pending
a2020q210-qexhibit312.htm Edgar Link pending
a2020q210-qexhibit321.htm Edgar Link pending
a2020q210-qexhibit322.htm Edgar Link pending
a2020q210-q_htm.xml Edgar Link completed
apyx-20200630.xsd Edgar Link pending
apyx-20200630_cal.xml Edgar Link unprocessable
apyx-20200630_def.xml Edgar Link unprocessable
apyx-20200630_lab.xml Edgar Link unprocessable
apyx-20200630_pre.xml Edgar Link unprocessable
apyxmedicallogotagline.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending